medigraphic.com

2013, Number 2

Next >>

Rev Cuba Endoc 2013; 24 (2)

Screening of asymptomatic impairments of glycemia is necessary

Buchaca FEF

Language: Spanish
References: 13
Page: 103-106
PDF size: 22.57 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Schmidt MI, Duncan BB, Bang H, Pankow JS, Ballantyne CM, Golden SH, Folsom AR, Chambless Ll, for the Atherosclerosis Risk in Communities Investigators. Identifying Individuals at High Risk for Diabetes The Atherosclerosis Risk in Communities study. Diabetes Care. 2005;28:2013-8.

  2. Yanes Quesada MÁ, Yanes Quesada M, Calderín Bouza R, Cruz Hernández J. Síndrome de insulinorresistencia, una amenaza para la salud. Rev Cubana Endocrinol [serie en Internet]. 2008 [citado 16 de abril de 2013];19(3). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561- 29532008000300006&lng=es&nrm=iso

  3. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2003;26:3160-7.

  4. Williams JW, Zimmet P, Shaw JE, de Courten MP, Cameron AJ, Chitson P, et al. Gender differences in the prevalence of impaired fasting glycaemia and impaired glucose tolerance in Mauritius. Does sex matter? Diabet Med. 2003;20:915-20.

  5. Matsuda M, DeFronzo RA. Relationship between insulin sensitivity in adipose tissue, liver, muscle, and components of the insulin resistance syndrome (Abstract). Diabetes. 1997;46:68A.

  6. Dor Y, Glaser B. Beta-Cell Dedifferentiation and Type 2 Diabetes. N Eng J Med. 2013;368:572-3.

  7. Bermúdez Rojas S, Buchaca Faxas E, Suárez del Villar Y, Rodríguez Amador L, Alonso Rodríguez CA, Mansur Luzardo M, et al. Trastornos de la glucemia y de la acción de la insulina en una población de riesgo de diabetes. Rev Cubana Endocrinol [serie en Internet]. 2009 [citado 16 de abril de 2013];20(3). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561- 29532009000300005&lng=es

  8. Bloomgarden Z. Cardiovascular disease in diabetes. Diabetes Care. 2008;31:1260-6.

  9. Pankow JS, Kwan DK, Duncan BB, Schmidt ML, Couper DJ, Golden S, Ballantyne CM. Cardiometabolic Risk in Impaired Fasting Glucose and Impaired Glucose Tolerance. The Atherosclerosis Risk in Communities Study. Diabetes Care. 2007;30:325-31.

  10. Barr E, Zimmet P, Welborn T, Jolley D, Magliano D, Dunstan D, et al. Risk of Cardiovascular and All-Cause Mortality in Individuals With Diabetes Mellitus, Impaired Fasting Glucose, and Impaired Glucose Tolerance: The Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation. 2007;116:151-7.

  11. Coca A. Resultados del Estudio CONTROLPRES 2003. Hipertensión. 2005;22:5-14.

  12. Absetz P, Oldenburg B, Hankonen N, Valve R, Heinonen H, Nissinen A, et al. Type 2 Diabetes Prevention in the Real World: Three-year Results of the GOAL Lifestyle Implementation Trial. Diabetes Care. August 2009;32:1418-20.

  13. American Diabetes Association. Standard of Medical Care in Diabetes-2013. Diabetes Care. 2013;36:S11-S66.




2020     |     www.medigraphic.com